Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions

Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.

Partnership

Eli Lilly and Company will partner with Dexcom, Glooko, Inc., myDiabby Healthcare and Roche Diabetes Care, which have developed diabetes management platforms that can be paired with Lilly’s TempoPen and Tempo Smart Button to help people manage their diabetes.

Lilly’s TempoPen is a modified version of its existing prefilled, disposable insulin pen. The Tempo Smart Button, which is pending the CE mark, attaches to the TempoPen.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.